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Abstract
Genetic predisposition, autoimmunity and environmental factors [e.g. pre- and perinatal difficulties, Group A Streptococcal 
(GAS) and other infections, stress-inducing events] might interact to create a neurobiological vulnerability to the develop-
ment of tics and associated behaviours. However, the existing evidence for this relies primarily on small prospective or larger 
retrospective population-based studies, and is therefore still inconclusive. This article describes the design and methodology 
of the EMTICS study, a longitudinal observational European multicentre study involving 16 clinical centres, with the follow-
ing objectives: (1) to investigate the association of environmental factors (GAS exposure and psychosocial stress, primarily) 
with the onset and course of tics and/or obsessive–compulsive symptoms through the prospective observation of at-risk 
individuals (ONSET cohort: 260 children aged 3–10 years who are tic-free at study entry and have a first-degree relative 
with a chronic tic disorder) and affected individuals (COURSE cohort: 715 youth aged 3–16 years with a tic disorder); (2) 
to characterise the immune response to microbial antigens and the host’s immune response regulation in association with 
onset and exacerbations of tics; (3) to increase knowledge of the human gene pathways influencing the pathogenesis of tic 
disorders; and (4) to develop prediction models for the risk of onset and exacerbations of tic disorders. The EMTICS study 
is, to our knowledge, the largest prospective cohort assessment of the contribution of different genetic and environmental 
factors to the risk of developing tics in putatively predisposed individuals and to the risk of exacerbating tics in young indi-
viduals with chronic tic disorders.
Keywords Genetics · Longitudinal · Obsessive–compulsive disorder · Stress · Streptococcal infection · Tourette syndrome
Introduction
Tic disorders are common, childhood-onset neuropsychiatric 
conditions characterised by the presence of sudden, rapid, 
recurrent, non-rhythmic motor movements (motor tics) and/
or vocalisations (vocal tics). Tic disorders are diagnosed 
when motor tics and vocal tics, either alone (chronic motor 
or vocal tic disorder) or in combination [Tourette syndrome 
(TS), manifesting with multiple motor tics and at least one 
vocal tic], begin before age 18 and last more than 1 year, 
in the absence of tics being attributable to a substance 
or another medical condition [1]. The prevalence of tics 
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during childhood/adolescence is close to 3%, and that of TS 
is approximately 0.8% between the ages of 6 and 18 years 
[2–4]. Tics and their associated neuropsychiatric comorbidi-
ties [attention-deficit/hyperactivity disorder (ADHD), obses-
sive–compulsive disorder (OCD), anxiety and depressive 
disorders, autism spectrum disorders] often affect quality of 
life of patients and families, as well as social and academic 
functioning of patients [5–9].
Our knowledge of the pathophysiological mechanisms 
involved in TS and other chronic tic disorders is still limited. 
Pharmacological and behavioural treatment options for TS 
represent the mainstay of treatment for tics, but both have 
limitations related to patients’ access to care, tolerability, 
and efficacy. In addition, at least 5% of patients with TS 
attending specialized clinics may have a very severe form 
that is refractory to non-invasive treatments [10]. There is 
still major need for new treatments and effective preventa-
tive methods, potentially fostered by a better understanding 
of disease pathophysiology.
TS is viewed as a complex neuropsychiatric disorder, 
which is likely to be related to an as yet poorly understood 
interaction between genetic and environmental susceptibility 
factors. While the heritability of TS has been estimated to 
be as high as 0.77 in a large scale multigenerational family 
study [11], a recent twin-family study found much lower 
heritability estimates, ranging between 0.25 and 0.37 [12], 
indicating a substantial role for environmental factors. The 
complex trait of tic disorders is polygenic, similar to most 
psychiatric disorders. Over the past decade, genetic factors 
associated with TS have been explored primarily through 
genome-wide approaches including genome-wide associa-
tion studies (GWASs), analysis of copy number variants 
(CNVs), and whole exome sequencing (WES) approaches. 
GWASs in TS have to date failed to identify highly genome-
wide significant loci [13, 14], likely due also to limited sam-
ple sizes, which were smaller than in other major psychiatric 
GWASs [15]. The contribution of rare structural variation to 
the genetic architecture of TS is supported by recent analyses 
of rare CNVs, which indicate that approximately 1% of TS 
cases carry one of these CNVs, highlighting also genome-
wide significant loci increasing TS risk, i.e. NRXN1 dele-
tions and CNTN6 duplications [16]. Like GWASs, WES 
studies in TS are also limited by their small sample sizes 
compared to other complex psychiatric traits; an associa-
tion with de novo damaging variants has been reported for 
a dozen candidate genes [17–20] and needs to be confirmed 
by studies with larger sample sizes. There is also a striking 
paucity of gene expression studies in tic disorders. Stud-
ies in this area focused on biological pathways related to 
neurotransmitters and immune regulation [17, 21–23], but 
were based on small sample sizes, did not clarify whether 
the observed changes were causes or consequences of the 
behavioural phenotype, and were never adequately combined 
to genomic data. Finally, the exploration of epigenetic modi-
fications associated with TS and other chronic tic disorders 
is still in its dawning [12, 24].
Some pre- and perinatal factors potentially interfering 
with normal brain development have been explored also in 
association with TS, although the related evidence differs 
for quality and methodology used across the different vari-
ables explored [e.g. 25–29]. During the past decade, a lim-
ited number of studies have also explored the contribution 
of psychosocial stress with overall inconclusive results, even 
if clinical experience does seem to support a role of stress 
in patients with TS [30]. A prospective evaluation based on 
questionnaires suggested an effect of psychosocial stress as 
a short-term predictor of tic severity [31]. Another study 
showed increased cortisol responses during acute stressors 
[32], but this was not confirmed by Buse et al. [33], who 
observed the opposite acute effect on a behavioural acute 
stress test (Trier Social Stress Test), coupled to salivary cor-
tisol determination and autonomic measures of the stress 
response. Obvious limitations of this literature are the lim-
ited sample sizes and the lack of longitudinal data exploring 
biological markers of acute and chronic stress, as well as 
direct measures of hypothalamic–pituitary–adrenal (HPA) 
axis activation.
An important research area, relevant to environmental 
influences in relation to tic disorders, is the involvement 
of abnormal innate and adaptive immune responses in the 
pathogenesis of tics and related behavioural symptoms 
[34]. A dysfunctional neural-immune cross-talk has been 
observed in patients with TS, in analogy to other neurodevel-
opmental disorders (e.g. autism spectrum disorder). Recent 
data from prospective population-based cohorts have dem-
onstrated a 30% increased incidence rate of TS in male off-
spring of women with an autoimmune disease [34], and a 
higher risk of any autoimmune disease among first-degree 
relatives of patients with OCD and chronic tic disorders [35]. 
Clinical studies have documented increased proliferation 
and activation of B and  TH1 lymphocytes, increased pro-
inflammatory cytokine levels, a decreased number of TREG 
lymphocytes, dysregulated immunoglobulin synthesis, sup-
porting the existence of adaptive immune responses skewed 
towards an inflammatory state TS [36, 37]. Furthermore, 
both post mortem data [38] and in vivo molecular imaging 
[39] suggest microglial activation in TS. Microglia cells are 
key players of the immune system in the central nervous 
system and play an increasingly recognized role in brain 
infections, neuroinflammation and neurodegeneration [40].
Alongside stress, infectious pathogens are obvious poten-
tial culprits for the overactivity of immune responses doc-
umented in tic disorders. A specific interest in a role for 
common infections (pharyngotonsillitis) caused by group 
A streptococcus (GAS or Streptococcus pyogenes) has been 
drawn by the description in 1998 of Paediatric Autoimmune 
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Neuropsychiatric Disorders Associated with Streptococcal 
Infections (PANDAS), a putatively autoimmune syndrome 
manifesting with obsessive–compulsive symptoms, tics, 
emotional lability, anxiety and regressive behaviour trig-
gered by this pathogen [41, 42]. In 2012, the broader syndro-
mic entity of Pediatric Acute Neuropsychiatric Syndromes 
(PANS) has been proposed, which encompasses PANDAS 
but includes other possible aetiologies [43]. Both PANS and 
PANDAS are viewed as a subtype of paediatric OCD and/or 
TS that present with an abrupt onset or exacerbation of neu-
ropsychiatric symptoms [44]. An autoimmune mechanism 
triggered by molecular mimicry between GAS bacterial 
and host neural antigens has been proposed for PANDAS, 
and putatively pathogenic biomarkers, e.g. autoantibodies 
directed against dopamine D2 receptors and antibody-medi-
ated calcium/calmodulin-kinase II activation in cell-based 
assays, have been reported and included in a proposed diag-
nostic panel (the Cunningham panel) [45, 46]. The diag-
nostic accuracy of this panel is, however, still discussed 
[47], and the potential usefulness of these biomarkers in 
highlighting an ‘autoimmune’ subgroup of patients with tic 
disorders is unexplored. More recent work has highlighted 
the rationale of exploring immune regulatory markers in this 
group of patients, and decreased systemic levels of vitamin 
D have been documented in an Italian cohort of patients 
with PANDAS [48]. Preliminary evidence reported the pres-
ence of anti-D2 dopamine receptor antibodies in a small 
proportion of individuals with TS Dale [49], supporting the 
rationale for further exploration of autoantibody markers in 
this condition.
Although tics are now considered an associated rather 
than a core feature of PANDAS and PANS [42], research-
ers have tried to address, during the past decade, the still 
unanswered question of whether and how infections, and 
above all GAS infections, are associated with the onset and/
or the exacerbation of tics and related behavioural symp-
toms. Large, retrospective, population-based cohort studies 
have provided some degree of evidence that GAS infections 
may be associated with the onset of tics [50–53] although 
discrepancies across studies exist [54]. At the same time, 
smaller, prospective studies have failed to show a clear 
association between GAS infections and tic exacerbations 
[55–59]. Nevertheless, one of these prospective studies 
reported a multiplicative interaction between GAS infec-
tions and psychosocial stress in predicting tic and obses-
sive–compulsive symptom severity in the short term [60]. 
Overall, these previous studies are limited by small sample 
sizes and some ambiguities in design (addressed in more 
depth in our “Discussion”), which justify the conduction of 
larger, more ambitious, prospective observations that take 
into account the complexity of the clinical phenomenol-
ogy of tic disorders, the genetic diversity of GAS, and the 
high inter-individual variability of GAS-induced immune 
responses [61]. An adequately sized clinic-based prospective 
study that collects behavioural, microbiological, immune-
endocrinological, genomic and transcriptomic data, pro-
vides a unique opportunity to advance the field by tackling 
some of the unanswered questions on the aetiopathogenesis 
of chronic tic disorders. The objectives and design of the 
multi-centre pan-European collaborative study EMTICS, 
funded by the European Commission seventh Framework 
programme (FP7), were conceived to address several of the 
knowledge gaps summarized above.
Core objectives of EMTICS
1. To investigate the association between putatively rel-
evant environmental factors, genome-wide genetic 
factors, and gene expression patterns upon the risk of 
developing clinically relevant exacerbations of tics and/
or OCD symptoms in youth with an established chronic 
tic disorder (COURSE cohort).
2. To investigate the association between putatively rel-
evant environmental factors, genome-wide genetic 
factors, and gene expression patterns upon the risk of 
new onset of tics in children who are first-degree rela-
tives of patients with an established chronic tic disorder 
(ONSET cohort).
For the first and second objectives, the explored envi-
ronmental exposures comprise: recent GAS infection, GAS 
carriage status, other recent infections, fluctuations of psy-
chosocial stress, cortisol as a marker of chronic stress and 
pre- and perinatal adversities.
3. To characterise patterns of the host innate and adap-
tive immune responses that are associated with clinical 
events of interest, i.e. onset of tics and clinically rel-
evant exacerbations of tics and/or OCD symptoms in 
the two clinical cohorts. This will comprise analyses 
of immune effectors (e.g. cytokines, immunoglobulins, 
acute phase reactants, other effector molecules including 
those belonging to the tryptophan/kynurenine pathway 
and vitamin D) and immune cell phenotyping.
4. To characterise patterns of the host antibody response to 
GAS and other pathogens previously reported in asso-
ciation with chronic tic disorders. The anti-GAS anti-
body patterns will be investigated with state-of-the-art 
microarray technology.
5. To develop multimodal prediction models for the risk 
of onset of tics in first-degree relatives of patients with 
chronic tic disorders, as well as for the risk of clinically 
relevant exacerbations of tics and/or OCD symptoms in 
youth with an established chronic tic disorder.
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Methods
Participants
Children aged 3–16 years were recruited from the sixteen 
child and adolescent psychiatry and paediatric neurology 
outpatient clinics (listed in the “Appendix”), from patients 
and families already known to these services or through 
advertisement of the study to patient organizations and 
other health professionals. This project was based on two 
separate cohort studies: ONSET and COURSE. The study 
was approved by the Institutional Review Boards of the 
participating centres. Parents and their child (ren) pro-
vided written informed consent and assent as appropri-
ate according to ethical regulations. While travel costs of 
participating families were reimbursed no additional fees 
were paid to participants. The first participant was enrolled 
in EMTICS in January 2013 and the study has concluded 
with the last visit of the last ONSET patients in June 2018.
Inclusion criteria
For the ONSET cohort, children aged 3–10 years were 
recruited who are first-degree relatives (siblings or chil-
dren) of patients with TS or another chronic tic disorder 
(criteria according to the Diagnostic and Statistical Man-
ual fourth edition, text revision [62]), but had themselves 
never had tics, OCD or trichotillomania. This age range 
reflects the range of age at first onset of tics in chronic 
tic disorders, as reported by the majority of naturalistic 
studies on these conditions [63]. For the COURSE cohort, 
patients aged 3–16 years with an established diagnosis 
of TS or chronic motor or vocal tic disorder according to 
DSM IV-TR criteria [62] were recruited. More than one 
sibling per family could participate in both studies.
Exclusion criteria
Children unable to understand and comply with protocol, 
or whose parents were unable to comply, and children with 
serious medical/neurological illness or treated with antibi-
otics in the past month were excluded from both ONSET 
and COURSE cohorts. The presence of comorbid neu-
ropsychiatric conditions such as autism spectrum disorder 
was not an exclusion criterion, nor was suspected PANS 
or PANDAS. Use of medications was not an exclusion 
criterion; however, all medication a child was taking dur-
ing the study was recorded. Children who refused throat 
swabs, blood draws or hair strains could still participate 
in the studies.
Study design and procedures
Longitudinal study ONSET
The ONSET study examines the association of the new 
onset of tics with exposure to pharyngeal GAS carriage or 
infection and other environmental and genetic factors, using 
clinical and laboratory assessments, over a 3-year period 
where the onset of tics represents the event of interest. Par-
ticipants were evaluated every 2 months, interchangeably 
by 4-monthly scheduled hospital visits and telephone inter-
views. Telephone interviews were scheduled in the middle 
of the 4 months’ intervals between hospital visits (see Fig. 1 
and supplementary Table 1). Irrespective of the planned visit 
schedule, parents were instructed to communicate any pos-
sible sign of tic onset to the study centre as soon as possible 
(e.g. by phone or email). To this purpose, all possible symp-
toms indicative of a possible onset of tics were thoroughly 
explained to parents at the baseline visit in ONSET.
Data collection was structured on three levels of obser-
vation: (1) through a weekly diary in which children’s par-
ents were asked to indicate symptom onset, aimed at the 
earliest possible detection of onset of tics throughout the 
whole study duration plus an inventory of signs of infectious 
disease (common cold), obsessive–compulsive symptoms 
and stressful events; (2) scheduled telephone interview once 
every 4 months with review of the weekly diaries since the 
last assessment and clinical evaluations performed by the 
study clinician to children’s parents; and (3) visits in hospital 
every 4 months over the 3-year duration of the follow-up 
period, which comprised a more extensive clinical evalu-
ation and collection of biological specimens (for measure-
ments see Table 1).
If parents reported possible onset of tics outside of 
planned visits or telephone interviews, an “unscheduled 
tic onset evaluation telephone interview” was held by the 
study clinician to investigate whether possible onset of tics 
had occurred. Tic onset was defined as the first occurrence 
of any sudden, rapid, recurrent, non-rhythmic involuntary 
motor movement and/or vocalisation noticed on at least three 
separate days within a period of 3 weeks. If the evaluation 
pointed to a possible tic onset (even when somewhat unsure), 
an “onset of tics hospital visit” was scheduled preferably 
within 1 week or at the earliest opportunity for extended 
clinical evaluation and collection of biological material. This 
served to assess the range of tics and/or obsessive–compul-
sive symptoms, symptoms and signs of infection (through 
throat swabs and blood tests for immunological markers of 
infection).
An “onset of tics hospital visit” was also scheduled 
when a (not previously reported) possible onset of tics was 
detected during a scheduled telephone interview while 
reviewing parents’ weekly diaries over the past 2 months 
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since the last assessment. Likewise, a planned follow-up 
hospital visit was turned into an “onset of tics hospital 
visit” when a possible onset of tics was confirmed during 
the planned visit. If tic onset occurred, all further planned 
assessments were discarded whereas a final follow-up 
visit was scheduled 1 year later that consisted of a clinical 
evaluation to confirm the true onset and type of tic disorder 
(according to DSM-IV-TR criteria) [62]. If an onset of tics 
was definitely not confirmed (e.g. tic-like phenomena could 
be better explained as symptoms of allergy or infectious 
disease), then the original visit schedule was retained. The 
maximum duration of the follow-up period was 3 years from 
enrolment if there was no tic onset (concluding with a “final 
non-tic onset visit”; a maximum of ten planned hospital vis-
its and nine telephone interviews took place; see supple-
mental Table 1), and a maximum of 4 years from enrolment 
if tics developed (concluding with a “final tic onset 1-year 
follow-up visit”, see Fig. 1).
Possible tic onset detected during tele interview
Parents report possible onset of tics to study team
Turn final visit into tic onset visit 
in case of tic onset and schedule 
1-year follow-up visit
8 weeks 
8 weeks 
Baseline
Tele 1 
Follow-up visit 1
Tele 2
Follow-up visit 2
Tele 3
Follow-up visit 3 …up to 8
Tele 4 ….up to 9
Final Non-Tic Onset Visit
aer 3 years
Turn follow-up visit into onset of 
tics visit in case of tic onset 
Plan onset of tics visit
within one week or 
soonest occasion
1 year 
1 year 
Onset of Tics Hospital Visit
Telephone interview confirms 
possible c onset
Final Tic Onset 1-Year 
Follow-up Visit
8 weeks 
Fig. 1  ONSET study flow chart. Tele telephone interview. If no tic 
onset was detected and confirmed then the original assessment sched-
ule (left side) was retained. After an onset of tics visit, all assess-
ments were discarded, except for a 1-year follow-up visit. The mini-
mum study period was 1 year, tic onset at the final visit increased the 
maximum study period to 4 years
96 European Child & Adolescent Psychiatry (2019) 28:91–109
1 3
Longitudinal study COURSE
The COURSE study is a cohort study that prospectively 
observed over a maximum period of 18 months 715 children 
and adolescents with an age range of 3–16 years affected 
by a tic disorder [62], where exacerbations of tics repre-
sent the events of interest. Data collection was analogous to 
the ONSET study, with interchanging 4-monthly planned 
hospital visits and telephone interviews as well as parental 
weekly diaries aimed at identifying tic exacerbations (see 
Fig. 2 and supplementary Tables 2 and 3).
Similar to the ONSET protocol, parents were asked to 
report any noticeable increase in tic severity, seemingly 
unrelated to a reduction or discontinuation of prescribed 
medication, to the study team. If the study clinician sub-
sequently through an unscheduled telephone interview 
Table 1  Summary of clinical and laboratory measurements at ONSET visits
See the main text for a description of measures
a The purpose of this visit was to establish whether the onset of tics was indeed indicative of the onset of a chronic tic disorder and to assess the 
possible presence of comorbidity
b Also assessed during 4-monthly telephone interviews
c No PSS-C-10
d PSS-P-4 during 4-monthly telephone interviews
e Only for follow-up visits #3 and #6
f Antibody responses to Group A streptococcal infections and other infectious pathogens including Anti-streptolysin O (ASO) and anti-deoxyrib-
onuclease B antibody titres (anti-DNAse B), cytokines, inflammatory status (C-reactive protein), and autoantibodies
g ASO and anti-DNAse B measurements only
h For immune response analyses only in a sub-sample of participants
Baseline visit 4-monthly 
follow-up visit
Tic onset visit Final visit 1-year 
post-tic  onseta
Final visit 
without tic 
onset
Demographics and family medical history ✓
Child’s medical history ✓ ✓ (update) ✓ (update)
Inventory of infections ✓ ✓b ✓ ✓
Psychotropic drug checklist ✓ ✓ ✓ ✓ ✓
Prenatal, perinatal and developmental history ✓
Exploration of possible tic onset ✓b ✓
YGTSS ✓ ✓
PUTS ✓ ✓
CY-BOCS ✓ ✓ ✓ ✓ ✓
CGI-S (tics) ✓ ✓
CGI-S (overall) ✓ ✓ ✓ ✓ ✓
CGI-I (overall) ✓ ✓ ✓ ✓
Tic disorder diagnosis ✓
OCD diagnosis ✓ ✓
ADHD diagnosis ✓ ✓ ✓
Trichotillomania diagnosis ✓ ✓
SDQ ✓ ✓ ✓ ✓ ✓
SNAP-IV ✓ ✓ ✓ ✓ ✓
ASSQ ✓
Kindl-R ✓ ✓ ✓ ✓ ✓
PSS-P-10; PSS-C-10 (≥ 11 years) ✓c ✓d ✓ ✓
Inventory of stressful events ✓ ✓b ✓ ✓
Throat swab ✓ ✓e ✓ ✓
Serum sample for immune  analysesf ✓ ✓g ✓ ✓
Fresh blood  sampleh ✓ ✓
Blood sample for DNA ✓
Blood sample for RNA ✓ ✓
Hair sample for cortisol analysis ✓ ✓ ✓ ✓
97European Child & Adolescent Psychiatry (2019) 28:91–109 
1 3
confirmed a tic exacerbation, defined as an increase of at 
least six points on the total tic severity score (i.e. sum of 
motor and vocal tic severity, but not impairment) of the 
Yale Global tic severity scale (YGTSS) [64] compared to 
the score during the previous assessment, an appointment for 
an expedited visit was scheduled preferably within 1 week, 
but no more than within 4 weeks. This expedited visit was 
followed by a “post-exacerbation visit” 2 months later, 
aimed at capturing tic remission, defined as a subsequent 
decrease of at least six points on the total tic severity score. 
Thereafter, a bi-monthly schedule of either a telephone 
interview or hospital visit was resumed. In COURSE, the 
total number of hospital visits was five with four planned 
telephone interviews, or six visits when an exacerbation had 
occurred at the final visit; a maximum number of two pairs 
of exacerbation plus post-exacerbation visits were possible 
Parents report possible tic exacerbation to study team
Possible exacerbation detected during tele interview
Turn final visit into expedited 
visit in case of tic exacerbation 
and plan extra final/post-
exacerbation visit
Resume schedule with next 
telephone interview
Turn follow-up visit into expedited 
visit in case of tic exacerbation 
8 weeks 
Baseline
Tele 1 
Follow-up visit 1
Tele 2
Follow-up visit 2
Tele 3
Follow-up visit 3
Tele 4
Final Visit 
Plan expedited 
visit as soon as 
possible,  within 
4 weeks
8 weeks 
8 weeks 
Expedited Visit  
(Tic Exacerbaon)
Post-Exacerbaon 
Expedited Visit 
Telephone interview confirms
c exacerbaon:
Increase ≥ 6 points on YGTSS
Combined Final/Post-
Exacerbaon Visit 
8 weeks 
8 weeks 
Fig. 2  COURSE study flow chart. Tele telephone interview, YGTSS 
Yale Global Tic Severity Scale. If no tic exacerbation was detected 
and confirmed then the original 16 month assessment schedule (left 
side) was retained. The maximum study period was 18 months if a tic 
exacerbation was detected at the final visit. A maximum of two pairs 
of expedited and post-exacerbation visits was possible. Expedited vis-
its shortened the study period accordingly
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(see supplementary Table 3 for the different measurement 
scenarios).
An exacerbation of tics (not previously reported by par-
ents) may also have been detected during the bi-monthly 
assessments either through telephone or hospital visit while 
reviewing the weekly diaries. While preferably the exacerba-
tion should then still be ongoing it was allowed to schedule 
an expedited visit within 4 weeks of the tic exacerbation. 
Thus, it may have occurred that tic severity was already in 
remission at the time of the expedited visit. If a tic exacer-
bation came under the attention during a planned follow-up 
visit, then the visit was turned into an “expedited tic exac-
erbation visit”. Finally, in some of the participating clinical 
sites, COURSE participants were considered for inclusion in 
a separate antibiotic treatment study if their microbiological 
testing revealed a positive culture for GAS.
Missed visits and end of study
Planned follow-up hospital visits and telephone interviews 
as well as “post-exacerbation visits” could be scheduled 
2 weeks earlier or later than according to the visit schedule 
(see supplementary Tables 1 and 2; except “tic onset visits” 
that could be scheduled at the earliest opportunity, or “expe-
dited tic exacerbation visits” and “final visits” that could 
be scheduled with a delay of up to 4 weeks). If this was not 
possible, the visit or interview was considered missed. Three 
consecutive missed appointments (visits or telephone inter-
views) led to study discontinuation. Children not keeping 
weekly diaries could still continue to participate in the study.
Study end is the date of the last visit of the last partici-
pant; for the ONSET study this is after 3 years after baseline 
in case of no tic onset; or 1 year after onset of tics with a 
maximum of 4 years. For the COURSE study, this is after 
16 months or less if there were tic exacerbations, and a max-
imum of 18 months when a tic exacerbation was identified 
during the planned final visit.
Clinical and laboratory measures
Clinical measures
Tables 1, 2, 3 present a summary of clinical and labora-
tory measurements at ONSET and COURSE visits, respec-
tively. The main outcome measure for both cohort studies is 
based on the YGTSS, the gold standard instrument to rate 
tic severity, which has robust psychometric properties [64]. 
Another main, well-validated measure was the Children’s 
Yale Brown Obsessive–Compulsive Scale (CY-BOCS; [65]), 
used to rate obsessive–compulsive symptom severity. Study 
clinicians well-experienced in the evaluation and treatment 
of tic disorders and associated conditions used these semi-
structured interviews to assess past week symptom severity 
and the current and past presence of tic disorders, OCD, and 
attention-deficit/hyperactivity disorder (ADHD) according 
to DSM-IV-TR criteria [62]. Clinicians also rated the Clini-
cal Global Impression Scale Severity for overall functioning 
and/or tics (CGI-S for severity and CGI-I for improvement) 
[66] and checked a list of psychotropic medication use dur-
ing the past 2 weeks.
A set of parent-reported questionnaires was used to assess 
participants’ demographics, the child’s medical history (e.g. 
immune-related conditions such as allergic rhinitis or atopic 
dermatitis), family medical history (psychiatric, neurologic 
and autoimmune diseases) [66], prenatal, perinatal and 
developmental history (Modified Schedule for Risk and 
Protective factors Early in Development, MSRPFED) cap-
turing 38 possible adverse situations [28, 67, 68] and degree 
of child experienced psychosocial stress over the previous 
month by the Perceived Stress Scale (PSS-P-10 at hospital 
visits; PSS-P-4 in telephone interviews) [69]. Parent rat-
ings of child’s psychopathological symptoms included the 
Strengths and Difficulties Questionnaire (SDQ) [70, 71], the 
Swanson, Nolan and Pelham-version IV rating scale (SNAP-
IV) [72, 73] to assess ADHD severity, and the Autism Spec-
trum Screening Questionnaire (ASSQ) [74]. Finally, the 
Kindl-R questionnaire (4–7 and 8–16 years parent versions) 
[75] measured health-related impact on the quality of life.
Child reports were the Premonitory Urge for Tics Scale 
(PUTS) [76], which measures unpleasant sensorimotor phe-
nomena that often precede tics and the self-reported Per-
ceived Stress Scale (PSS-C-10) [69]) in children ≥ 11 years. 
The weekly diaries covered an inventory of possible infec-
tions (i.e. symptoms of common cold such as running nose, 
persistent cough or fever) and related diagnosis and treat-
ment, possible medication changes, occurrence of stressful 
events, and possible onset of tics or fluctuations (especially 
exacerbations) in tics and OCD symptoms.
Laboratory measures
See Table 3 for an overview of laboratory measures. The 
main microbiological measures were GAS colonisation by 
throat swabbing and processing using a consensus-defined 
methodology (pour plate method) [55, 77]. The microbio-
logical typing of bacterial GAS population was performed 
by emm typing, Multiple Locus Variable number of tandem 
repeats Analysis (MLVA) and Multi Locus Sequence Typ-
ing (MLST). Exposure to GAS in study participants was 
investigated by measuring anti-streptolysin O titre (ASOT) 
and anti-DNAseB antibody titre. Moreover, protein micro-
array technology described elsewhere by one of the teams 
participating in the EMTICS consortium [61] was used to 
compare the patterns of antibody responses to a panel of 
GAS antigens in ONSET participants who have or have not 
developed tics. By the same approach, antibody profiles 
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in the COURSE participants were compared pre and post 
exacerbation.
Other performed serum immune measurements included 
measurement of IgA-, IgM- and IgG-titres against Myco-
plasma pneumoniae, Chlamydia spp., Epstein–Barr virus 
(EBV), Borrelia burgdorferi, and Toxoplasma gondii; 
sCD14, interleukin-6, interleukin-17, tumor necrosis factor 
(TNF)-α, TNF-RI, TNF-RII, immunoglobulin (IgA, IgM, 
IgG) subclasses, and ratio between pentameric and mono-
meric CRP to examine the possibility of impaired resolution 
of inflammation; tryptophan, kynurenine, kynurenic acid, 
3-hydroxykynurenine, xanthurenic acid, anthranilic acid, 
3-hydroxyanthranilic acid, quinolinic acid, picolinic acid, 
5-hydroxyindoleacetic acid and other important intermedi-
ates of the tryptophan pathway. Furthermore, the vitamin 
D status was measured and in a small sub-sample, immune 
cell-based measures include phenotyping for the main innate 
and adaptive immunological cell types, including T cells 
(CD3, CD4, CD8), B cells (CD19) and natural killer cells 
(CD56+). Functional analysis assessed the production of 
inflammatory cytokines post-stimulation/activation by bac-
terial pathogen triggers. Autoantibodies measured in serum, 
by cell-based assay [49] included anti-neuronal antibodies 
targeting candidate self-antigens for post-streptococcal 
Table 2  Summary of clinical and laboratory measurements at COURSE visits
See the main text for a description of measures
a Two months after the expedited visit to capture possible tic remission
b Also assessed during 4-monthly telephone interviews
c PSS-P-4 during 4-monthly telephone interviews
d Antibody responses to Group A streptococcal infections and other infectious pathogens including anti-streptolysin O (ASO) and anti-deoxyribo-
nuclease B antibody titres (anti-DNAse B), cytokines, inflammatory status (C-reactive proteins), and autoantibodies
e ASO and anti-DNAse B measurements only
f For immune response analyses only in a sub-sample of participants
Baseline visit 4-monthly 
follow-up visit
Expedited visit in case 
of tic exacerbation
Post-exacerba-
tion  visita
Final visit
Demographics and family medical history ✓
Child’s medical history ✓ ✓ (update)
Inventory of infections ✓ ✓b ✓ ✓ ✓
Psychotropic drug checklist ✓ ✓ ✓ ✓ ✓
Prenatal, perinatal and developmental history ✓
Evaluation of possible tic exacerbation ✓b ✓
YGTSS ✓ ✓b ✓ ✓ ✓
PUTS ✓ ✓ ✓ ✓ ✓
CY-BOCS ✓ ✓b ✓ ✓ ✓
CGI-S (overall and tics) ✓ ✓ ✓ ✓ ✓
CGI-I (overall and tics) ✓ ✓ ✓ ✓
Tic disorder diagnosis ✓ ✓
OCD diagnosis ✓ ✓
ADHD diagnosis ✓ ✓
Trichotillomania diagnosis ✓ ✓
SDQ ✓ ✓ ✓ ✓ ✓
SNAP-IV ✓ ✓ ✓ ✓ ✓
ASSQ ✓
Kindl-R ✓ ✓ ✓ ✓ ✓
PSS-P-10; PSS-C-10 (≥ 11 years) ✓ ✓c ✓ ✓ ✓
Inventory of stressful events ✓ ✓b ✓ ✓ ✓
Throat swab ✓ ✓ ✓ ✓ ✓
Serum sample for immune  analysesd ✓ ✓e ✓ ✓ ✓
Fresh blood  samplef ✓ ✓
Blood sample for DNA ✓
Blood sample for RNA ✓ ✓
Hair sample for cortisol analysis ✓ ✓ ✓ ✓ ✓
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neuropsychiatric disorders, mainly dopamine D2 receptors, 
in relation to onset or exacerbation of tic disorders.
Genome-wide genetic factors were investigated through 
the genotyping of participants using peripheral blood-
extracted DNA, genotyped on an Illumina Human OmniEx-
press array, targeting more than 700,000 common variants. 
Published genome-wide genotyping data for individuals of 
European descent are used for the control dataset to perform 
GWAS and identify single gene or gene–gene interactions 
associated with TS and obsessive–compulsive symptoms. 
The integration of EMTICS genetics data with existing 
datasets from parallel efforts from European and Ameri-
can consortia will enable a meta-analysis of a joint dataset 
with more than 8000 cases with TS and obsessive–compul-
sive symptoms. In addition, genome-wide gene expression 
data were investigated using peripheral blood-extracted 
total RNA, analysed on an Affymetrix Human Transcrip-
tome Array (HTA 2.0), targeting more than 285,000 cod-
ing and non-coding and alternatively spliced transcripts to 
unravel biological pathways that may influence the onset and 
clinical course of tics activated upon symptom exacerba-
tions and remissions. By combining genotyping and gene 
expression data with other laboratory measures, we aim to 
explore the complex interaction between the environmental, 
immunological and autoimmune factors related to the onset 
and clinical course of the disorder spectrum. Finally, we 
determined cortisol levels in hair, which is a biomarker 
of retrospective chronic stress [78] using a commercially 
available immunoassay with chemoluminescence detection 
(CLIA, IBL-Hamburg, Germany) [79, 80].
Sample size calculations
ONSET study
The ONSET study originally aimed to recruit 500 par-
ticipants but managed to include 260 children who are 
first-degree relatives of patients with a tic disorder, aged 
3–10 years. Still this sample size would allow us to obtain 
an estimated odds ratio of 2.85 for GAS carriers compared 
to non-carriers with respect to the event “onset”, using the 
pre-study assumptions of an estimated GAS carriage rate 
during childhood of 15% [81], and an estimated risk of 
30% [82] for a first-degree relative of a patient with TS or 
another chronic tic disorder to be affected by a tic disorder 
or OCD. Assuming a 15% GAS carriage rate and 30% risk 
of TS/OCD in siblings or children of patients with TS at 
age 3–10, to obtain an odds ratio of 2.2 for GAS carriers 
Table 3  Laboratory measures
See the “Appendix” for laboratory centres
Analysis Material Laboratory parameters and laboratories
GAS colonisation Throat swabs Bacterial group A streptococcal (GAS) population at each indi-
vidual centre
Anti-streptococcal antibody titres Serum Anti-streptolysin O (ASO), Anti-desoxyribonuclease B (anti-
DNAseB) at LMU
Antibodies to non-streptococcal pathogens Serum Mycoplasma pneumoniae (Myco_IgG), Chlamydia trachomatis 
(Chlamy_IgG), Epstein–Barr virus (EBV), Borrelia burgdorferi 
(Borrel_IgG), and Toxoplasma gondii (Toxo_IgG) at LMU
Anti-streptococcal immune response Serum Antibody responses to GAS multiple antigens at GSK
Autoantibodies by cell-based assay Serum Anti-neuronal antibodies targeting candidate self-antigens for post-
streptococcal neuropsychiatric disorders, mainly dopamine D2 
receptors at Bari
Cytokine receptors and immunoglobulins Serum Interleukin-6 (IL-6), interleukin-17F (IL-17F), tumor necrosis 
factor α (TNF-α), TNF-RI, TNF-RII, CD14, immunoglobulin 
subclasses (IgA, IgM, IgG1-4) at Cytolab
C-Reactive Protein (CRP) Serum Pentameric CRP (pCRP), Monomeric CRP (mCRP) at ApDia
Tryptophan and kynurenine pathway intermediates Serum Tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), 
3-hydroxykynurenine (3HK), xanthurenic acid (XAN), 
anthranilic acid (AA), quinolinic acid (QUIN), picolinic acid 
(PIC), 5-hydroxytryptophan (5-HTRP), 5-hydroxyindoleacetic 
acid (5HIAA), nicotinic acid (NAD) at LMU
Vitamin D Serum 25-OH-Vitamin D at LMU
T cells and NK cells Whole blood IFN-g, CD4/CD8, CD56/CD3 at ProImmune
Genotyping and gene expression PAXgene tubes 
(RNA), EDTA tubes 
(DNA)
Genome-wide genetic factors, genotyping and gene expression at 
deCODE Genetics and Biolytix
Hair cortisol Hair strains 2–4 cm Cortisol measuring chronic stress in hair at TUD
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compared to non-carriers with respect to the event “onset” 
with 80% power and 5% significance level (two-sided), we 
calculated a sample size of 319 using the Kelsey method. 
Assuming a 15% drop out a sample size of 375 patients 
allows this number to be achieved.
COURSE study
The COURSE study includes 715 children and adolescents 
affected by a tic disorder with an age range of 3–16 years. 
A target sample size of 700 was based on the following 
pre-study assumptions: we assumed it would allow us to 
obtain an estimated odds ratio of 2.45 for GAS carriers 
compared to non-carriers with respect to the event “exac-
erbation”, assuming an exposure to streptococcal infection 
of 0.12 and a rate of symptom exacerbation of 0.16 based 
on a conservative estimate from prior longitudinal studies 
of TS [58, 59]. The sample size for the COURSE study 
was calculated in an identical fashion to the ONSET study.
Genetic and gene expression analyses
The sample collected in this study will provide 96% 
power to detect genetic alleles of frequency > 0.3 confer-
ring risk > 1.5, to be analysed using existing tools (e.g. 
methods implemented in PLINK), as well as by design-
ing novel statistical and data mining techniques, aiming 
to uncover single gene, gene–gene and gene–environment 
interaction in TS/OCD pathogenesis. For gene expres-
sion group analysis, for a minimum total of 40 samples 
(20 samples per group), we can reach significant results 
(p < 0.05/16,000 = 3 × 10−6) with 98% power if considering 
about 16,000 genes remaining after quality control, with 
the gene(s) showing foldChange ≥ 2 (up/down regulation).
Statistical analysis
ONSET study
We will use logistic regression to evaluate risk factors for 
developing tics, while survival analysis (Cox proportional 
hazards model) will be performed to assess the effect of 
risk factors on the time of developing tics, allowing for 
clustering of patients within regions. We will also develop 
a risk model for the risk of new onset of tics in first-degree 
relatives of patients with chronic tic disorders. Cox pro-
portional hazards regression models (with adjustments for 
clustering) will be used to develop the risk model. Selec-
tion or shrinkage methods may be employed depending 
on the event rate.
COURSE study
Data analysis of the COURSE study will be directed at 
examining the association between the longitudinal course 
of tics and/or obsessive–compulsive symptoms and vari-
ous risk factors. Logistic regression will be used to evalu-
ate the effects of risk factors on the risk of tic exacerbation 
during the same or the subsequent follow-up period, while 
survival analysis (Cox proportional hazards model) will be 
performed to assess the effect of risk factors on the time to 
development of exacerbations, again allowing for clustering 
of patients within regions.
In both studies, exposure to GAS will be defined as new 
GAS throat carriage as evaluated on microbiological analy-
sis of the throat specimen (‘newly positive’ throat swab) OR 
as significant elevation of anti-streptococcal antibody titres, 
defined as follows: a significant elevation of anti-streptolysin 
O titre (ASOT) will be diagnosed when ASO > 200 AND 
[log10 (ASOcurrent visit) − log10(ASOprior visit)] ≥ 0.2 
(variation between log10 for two consecutive measure-
ments is higher than or equal to 0.2); a significant eleva-
tion of anti-DNAseB will be diagnosed when anti-DNAseB 
> 300 AND [log10 (anti-DNAseBcurrent visit) − log10(anti-
DNAseBprior visit)] ≥ 0.2 (variation between log10 for two 
consecutive measurements is higher than or equal to 0.2). 
In addition to the analyses above, the dataset of the ONSET 
and COURSE study provides ample opportunities to look 
into the relationship between immune parameters, infec-
tions, psychosocial stress, genetic factors and tic onsets and 
exacerbations.
Genetic analyses
Given the diverse origin of the samples that will be included 
in the produced data sets, particular attention will be paid to 
statistical techniques that correct for biases that are typically 
introduced in such analyses, due to population stratification. 
To assist in this, we will leverage the power of Principal 
Components Analysis to detect stratification and population 
substructure. To uncover gene–environment interactions, the 
case-only design and traditional (e.g. multi-dimensionality-
reduction) as well as machine-learning techniques will be 
used. The resulting list of target susceptibility variants will 
be refined through gene-network analysis and search of 
public databases of gene function and ontology. Quantita-
tive trait loci (QTLs) will be identified among the single 
nucleotide polymorphisms (SNPs) yielding results of high 
statistical significance to assist in the identification of pos-
sible gene pathways that are involved in the susceptibility to 
the studied disorders. Public gene expression databases (e.g. 
HapMap data of gene expression from lymphoblastoid cell 
lines) will be used to that effect.
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We will also mine for gene–gene and gene–environment 
interactions. In particular, we will attempt to leverage lin-
ear discriminant analysis (LDA), a powerful dimensionality 
reduction technique, to design statistical tests that analyse 
all the SNP genotypes from a GWAS simultaneously (as 
opposed to one at the time) and thus identify a subset of 
SNPs that are most associated or predictive of disease risk. 
This technique achieves improved performance over single 
SNP tests.
Gene expression analyses
Statistical tests (e.g. T tests, ANOVA, ANCOVA) will be 
performed using Partek, GeneSpring, PAM and BRB-Array-
Tools. Special care is going to be taken to correct for poten-
tial confounding factors (e.g. ancestry, sex, age). Multiple 
comparison corrections will be performed using Benjamini 
and Hochberg False Discovery Rate. A tenfold cross valida-
tion will be performed, and the minimum number of genes 
that predicts a given class will be derived using prediction 
analysis of microarrays (PAM) which uses a nearest neigh-
bour, smallest shrunken centroid algorithm. Other prediction 
algorithms including support vector machine methods will 
be used to confirm these results. Cluster analyses and prin-
cipal component analyses will be used to visualize how well 
the genes separate the groups, or to discover new classes.
Data management and data cleaning
All data were collected on paper and entered into an elec-
tronic data base by each site. The data in each site are 
encrypted and kept in a secured place, and were transmit-
ted in a secure manner, in line with requirements of data 
protection and data transmission regulations. At each site, 
a unique code was assigned to recruited members, and tests 
were delivered to the labs, withholding any identifying infor-
mation (e.g. name, initials, birth date). After collection of 
clinical data had been completed we checked all data for 
improbable values and corrections have been applied where 
needed by going back to source material. Data access to 
researchers from outside the EMTICS consortium research 
shall be granted on fair and reasonable conditions.
Training
All collaborators were trained in clinical assessments with 
a focus on the YGTSS by use of video recording of children 
with tics and in appropriate conduct of research in accord-
ance with ethical requirements. Moreover, throughout the 
6.5 years duration of the study we had bi-annual meetings 
with all investigators in which various aspects of the study 
were discussed aimed at standardisation of procedures and 
obtaining agreement. In addition, in case of diagnostic 
uncertainties, consensus scoring was used within the expert 
team of the respective clinical centres. The microbiologi-
cal methods used by different centres to isolate GAS from 
carriers with low bacterial density were harmonised and 
improved through a training course and two external qual-
ity assessments.
Discussion
The EMTICS study provides the unique opportunity to ana-
lyse data on a broad set of environmental exposures and 
biological markers related to chronic tic disorders under 
the umbrella of a common methodological framework. The 
ONSET cohort of the EMTICS study represents, to the best 
of our knowledge, the first attempt to capture in a prospec-
tive fashion the onset of tics in an at-risk population, i.e. 
first-degree relatives of probands with a chronic tic disorder. 
At the same time, the COURSE cohort of the EMTICS study 
represents, to date, the largest cohort of youth with a chronic 
tic disorder followed up systematically and in a prospective 
fashion to capture clinically relevant exacerbations of tics 
and/or OCD symptoms. It offers therefore the possibility 
to investigate, with larger power than previously sought, 
the potential determinants of severity fluctuations within 
these disorders. This type of design and dataset offers an 
as yet unforeseen opportunity to develop prediction models 
and algorithms that quantify the risk of onset or exacerba-
tion of tic disorders based on environmental exposures and 
gene–environment interactions. Such predictive algorithms 
would then need further validation in other populations 
before being introduced in routine clinical activity.
The previous studies that have tackled the multifactorial 
influence of environment and gene–environment interactions 
upon the natural history of chronic tic disorders were either 
population-based studies that used national health- or health 
insurance claims-based registries, or single- or multicentre, 
clinic-based, prospective studies. Population-based studies 
have reported associations of TS/chronic tic disorders and 
common comorbidities with a very specific environmental 
exposure such as GAS infections [50–54], with little or no 
insight on interactions between exposures. Although the 
majority of these studies reported an increased risk of tic 
disorders for individuals with a history of previous strepto-
coccal throat infection ranging between 1.2 and 2.2, these 
estimates vary across studies, and in at least one study [54] 
the association was not confirmed. The variability across 
health data registry studies in the definition of GAS infec-
tions as well as in the source and methodology of data col-
lection from different care providers possibly reasons for the 
discrepancies across risk estimates. Our prospective, hypoth-
esis-based study design overcomes this limitation, using a 
strict and standardized, homogenous and quality-controlled 
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determination of GAS colonisation. Moreover, our study 
design guarantees homogeneity, compared to population-
based studies, also with respect to the assessment of tic dis-
orders and concurrent symptoms through a trained group of 
clinicians, minimising medical surveillance bias and recall 
bias. We acknowledge, however, that some of the data col-
lected in EMTICS, e.g. those on pre- and perinatal adversi-
ties might also suffer from a certain degree of recall bias, 
in the lack of supporting medical documentation. Another 
advantage with respect to previous population-based studies 
is the possibility for correlating clinically relevant events or 
exposures to biological measures, which is key to under-
standing multifactorial interactions and elaborate mecha-
nistic explanations for the observed associations. The main 
limitation compared to population-based studies is the risk 
of a larger type II error, particularly in the ONSET cohort, 
linked to smaller study power.
Previous prospective, clinic-based studies enrolled 
smaller (N < 50 with the exception of [54] patient cohorts 
[55–59], often aiming to isolate a subgroup of patients with 
PANDAS from a clinic-based population of patients with a 
‘garden variety’ tic disorders. The research questions of the 
EMTICS study do not refer to the PANDAS or the PANS 
spectrum, and indeed clinical data gathered in EMTICS are 
insufficient to diagnose PANS accurately. Compared to pre-
vious clinic-based studies, EMTICS relies on rating scale 
based data to confirm or exclude exacerbations of tics, thus 
minimising a potential bias resulting from subjective defini-
tions of exacerbation based on the judgement of individual 
clinicians. Previous clinic-based studies have, in some cases 
[56, 59], applied a more intensive clinical follow-up over a 
period of 24 months, although this applied to a population of 
less than 90 patients. Logistic limitations related to the inter-
national composition of the EMTICS list of enrolment sites 
did not allow such an intensive follow-up for a very large 
population. We partially mitigated this potential limitation in 
the COURSE cohort by replacing highly frequent clinic vis-
its with the use of structured weekly diaries and bi-monthly 
telephone interviews in between clinic visits. A caveat of 
this logistic limitation is the greater reliance on self-reported 
data. Finally, prospective clinic-based studies did not ana-
lyse in detail interactions between exposures, with the only 
exception of the study by Lin et al. [59], which evaluated the 
interaction between GAS infections and psychosocial stress 
levels on a relatively small population of 45 cases with TS 
and/or OCD and 41 matched control subjects. The design of 
EMTICS appears highly promising to test this interaction 
with a substantially greater statistical power.
Albeit comprehensive, the EMTICS study does not 
include all the potential pathophysiological biomarkers of 
TS that could be influenced by environmental exposures and 
gene–environment interactions, e.g. imaging of brain net-
works or microbiome data. The EMTICS research platform 
has, however, included parallel studies of animal models that 
aim to replicate some of the pathophysiological constructs 
explored by clinical studies. Some of these animal model 
data have already been published [83–85] and a detailed 
explanation of these pre-clinical studies is beyond the scope 
of this article. We acknowledge that other comorbid behav-
ioural symptoms, e.g. ADHD symptoms, may also fluctuate 
over time in patients with tic disorders; however, we focused 
on the prospective evaluation of tics and obsessive–com-
pulsive symptoms, as preliminary studies reported a similar 
short-term influence of putative environmental risk factors 
(psychosocial stress, GAS infections) on both tic and obses-
sive–compulsive symptom severity.
Lastly, one concern regarding the gene expression study 
in EMTICS has been whether peripheral blood can mirror 
the neuronal tissue, when it comes to detecting altered gene 
expression profiles that could be relevant to brain pathol-
ogy. However, recent data support the fact that changes of 
gene expression in blood may actually constitute distinct 
molecular signatures of not only clearly hereditary disorders 
(e.g. neurofibromatosis type I, tuberous sclerosis complex 
2, Down’s syndrome [86]; Huntington’s disease Borovecki 
[87]), but also complex disorders of the brain (multiple 
sclerosis [88]; migraine and TS [89, 90]). Thus, there has 
been considerable effort in determining whether blood gene 
expression profiling can provide surrogate markers for neu-
rological diseases, including TS, especially when consider-
ing (1) the inaccessibility of the actual diseased tissue, and 
(2) the often very young age of cases with TS participating 
in research studies, such as EMTICS. In fact, it was recently 
shown that distinct gene expression changes were correlated 
with tic severity in medicated versus unmedicated TS cases 
[91], whereas specific molecular signatures were correlated 
with inattention and hyperactivity/impulsivity, a very com-
mon TS comorbidity, in individuals with TS [92]. Therefore, 
we believe that EMTICS may further elucidate the genetic 
background underlying tic disorders and to may shed light 
on how these interact with environmental factors influencing 
the onset and clinical course of tic disorders.
We conclude that this study, the first European study of 
TS of this size granted by the EU, provides innovative and 
unique avenues to address the aetiology of chronic tic dis-
orders, and we hope that it will represent the consolidation 
of a stable collaborative research and clinical environment 
on TS and related disorders in Europe.
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